1 Introduction to Research & Analysis Reports
1.1 Antidepressant Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Antidepressant Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Antidepressant Drugs Overall Market Size
2.1 Global Antidepressant Drugs Market Size: 2022 VS 2029
2.2 Global Antidepressant Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Antidepressant Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Antidepressant Drugs Players in Global Market
3.2 Top Global Antidepressant Drugs Companies Ranked by Revenue
3.3 Global Antidepressant Drugs Revenue by Companies
3.4 Global Antidepressant Drugs Sales by Companies
3.5 Global Antidepressant Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Antidepressant Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Antidepressant Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Antidepressant Drugs Players in Global Market
3.8.1 List of Global Tier 1 Antidepressant Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Antidepressant Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Antidepressant Drugs Market Size Markets, 2022 & 2029
4.1.2 SSRIs
4.1.3 SNRIs
4.1.4 TCAs
4.1.5 MAOIs
4.1.6 TeCAs
4.1.7 NaSSAs
4.1.8 RMAO-A Inhibitors
4.2 By Type – Global Antidepressant Drugs Revenue & Forecasts
4.2.1 By Type – Global Antidepressant Drugs Revenue, 2018-2023
4.2.2 By Type – Global Antidepressant Drugs Revenue, 2024-2029
4.2.3 By Type – Global Antidepressant Drugs Revenue Market Share, 2018-2029
4.3 By Type – Global Antidepressant Drugs Sales & Forecasts
4.3.1 By Type – Global Antidepressant Drugs Sales, 2018-2023
4.3.2 By Type – Global Antidepressant Drugs Sales, 2024-2029
4.3.3 By Type – Global Antidepressant Drugs Sales Market Share, 2018-2029
4.4 By Type – Global Antidepressant Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Antidepressant Drugs Market Size, 2022 & 2029
5.1.2 Anxiety Disorders
5.1.3 Eating Disorders
5.1.4 Pain
5.1.5 Others
5.2 By Application – Global Antidepressant Drugs Revenue & Forecasts
5.2.1 By Application – Global Antidepressant Drugs Revenue, 2018-2023
5.2.2 By Application – Global Antidepressant Drugs Revenue, 2024-2029
5.2.3 By Application – Global Antidepressant Drugs Revenue Market Share, 2018-2029
5.3 By Application – Global Antidepressant Drugs Sales & Forecasts
5.3.1 By Application – Global Antidepressant Drugs Sales, 2018-2023
5.3.2 By Application – Global Antidepressant Drugs Sales, 2024-2029
5.3.3 By Application – Global Antidepressant Drugs Sales Market Share, 2018-2029
5.4 By Application – Global Antidepressant Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Antidepressant Drugs Market Size, 2022 & 2029
6.2 By Region – Global Antidepressant Drugs Revenue & Forecasts
6.2.1 By Region – Global Antidepressant Drugs Revenue, 2018-2023
6.2.2 By Region – Global Antidepressant Drugs Revenue, 2024-2029
6.2.3 By Region – Global Antidepressant Drugs Revenue Market Share, 2018-2029
6.3 By Region – Global Antidepressant Drugs Sales & Forecasts
6.3.1 By Region – Global Antidepressant Drugs Sales, 2018-2023
6.3.2 By Region – Global Antidepressant Drugs Sales, 2024-2029
6.3.3 By Region – Global Antidepressant Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Antidepressant Drugs Revenue, 2018-2029
6.4.2 By Country – North America Antidepressant Drugs Sales, 2018-2029
6.4.3 US Antidepressant Drugs Market Size, 2018-2029
6.4.4 Canada Antidepressant Drugs Market Size, 2018-2029
6.4.5 Mexico Antidepressant Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Antidepressant Drugs Revenue, 2018-2029
6.5.2 By Country – Europe Antidepressant Drugs Sales, 2018-2029
6.5.3 Germany Antidepressant Drugs Market Size, 2018-2029
6.5.4 France Antidepressant Drugs Market Size, 2018-2029
6.5.5 U.K. Antidepressant Drugs Market Size, 2018-2029
6.5.6 Italy Antidepressant Drugs Market Size, 2018-2029
6.5.7 Russia Antidepressant Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Antidepressant Drugs Market Size, 2018-2029
6.5.9 Benelux Antidepressant Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Antidepressant Drugs Revenue, 2018-2029
6.6.2 By Region – Asia Antidepressant Drugs Sales, 2018-2029
6.6.3 China Antidepressant Drugs Market Size, 2018-2029
6.6.4 Japan Antidepressant Drugs Market Size, 2018-2029
6.6.5 South Korea Antidepressant Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Antidepressant Drugs Market Size, 2018-2029
6.6.7 India Antidepressant Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Antidepressant Drugs Revenue, 2018-2029
6.7.2 By Country – South America Antidepressant Drugs Sales, 2018-2029
6.7.3 Brazil Antidepressant Drugs Market Size, 2018-2029
6.7.4 Argentina Antidepressant Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Antidepressant Drugs Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Antidepressant Drugs Sales, 2018-2029
6.8.3 Turkey Antidepressant Drugs Market Size, 2018-2029
6.8.4 Israel Antidepressant Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Antidepressant Drugs Market Size, 2018-2029
6.8.6 UAE Antidepressant Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Antidepressant Drugs Major Product Offerings
7.1.4 Pfizer Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Mylan
7.2.1 Mylan Company Summary
7.2.2 Mylan Business Overview
7.2.3 Mylan Antidepressant Drugs Major Product Offerings
7.2.4 Mylan Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Mylan Key News & Latest Developments
7.3 Bayer
7.3.1 Bayer Company Summary
7.3.2 Bayer Business Overview
7.3.3 Bayer Antidepressant Drugs Major Product Offerings
7.3.4 Bayer Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Bayer Key News & Latest Developments
7.4 Eli Lilly
7.4.1 Eli Lilly Company Summary
7.4.2 Eli Lilly Business Overview
7.4.3 Eli Lilly Antidepressant Drugs Major Product Offerings
7.4.4 Eli Lilly Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Eli Lilly Key News & Latest Developments
7.5 Claire Ellen
7.5.1 Claire Ellen Company Summary
7.5.2 Claire Ellen Business Overview
7.5.3 Claire Ellen Antidepressant Drugs Major Product Offerings
7.5.4 Claire Ellen Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Claire Ellen Key News & Latest Developments
7.6 Sanofi S.A
7.6.1 Sanofi S.A Company Summary
7.6.2 Sanofi S.A Business Overview
7.6.3 Sanofi S.A Antidepressant Drugs Major Product Offerings
7.6.4 Sanofi S.A Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Sanofi S.A Key News & Latest Developments
7.7 Meda AB
7.7.1 Meda AB Company Summary
7.7.2 Meda AB Business Overview
7.7.3 Meda AB Antidepressant Drugs Major Product Offerings
7.7.4 Meda AB Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Meda AB Key News & Latest Developments
7.8 Boehringer Ingelheim
7.8.1 Boehringer Ingelheim Company Summary
7.8.2 Boehringer Ingelheim Business Overview
7.8.3 Boehringer Ingelheim Antidepressant Drugs Major Product Offerings
7.8.4 Boehringer Ingelheim Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Boehringer Ingelheim Key News & Latest Developments
7.9 Pierre Fabre
7.9.1 Pierre Fabre Company Summary
7.9.2 Pierre Fabre Business Overview
7.9.3 Pierre Fabre Antidepressant Drugs Major Product Offerings
7.9.4 Pierre Fabre Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Pierre Fabre Key News & Latest Developments
7.10 Cipla
7.10.1 Cipla Company Summary
7.10.2 Cipla Business Overview
7.10.3 Cipla Antidepressant Drugs Major Product Offerings
7.10.4 Cipla Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Cipla Key News & Latest Developments
7.11 APOTEX
7.11.1 APOTEX Company Summary
7.11.2 APOTEX Antidepressant Drugs Business Overview
7.11.3 APOTEX Antidepressant Drugs Major Product Offerings
7.11.4 APOTEX Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.11.5 APOTEX Key News & Latest Developments
7.12 PRINSTON INC
7.12.1 PRINSTON INC Company Summary
7.12.2 PRINSTON INC Antidepressant Drugs Business Overview
7.12.3 PRINSTON INC Antidepressant Drugs Major Product Offerings
7.12.4 PRINSTON INC Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.12.5 PRINSTON INC Key News & Latest Developments
7.13 TEVA
7.13.1 TEVA Company Summary
7.13.2 TEVA Antidepressant Drugs Business Overview
7.13.3 TEVA Antidepressant Drugs Major Product Offerings
7.13.4 TEVA Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.13.5 TEVA Key News & Latest Developments
7.14 ROXANE
7.14.1 ROXANE Company Summary
7.14.2 ROXANE Business Overview
7.14.3 ROXANE Antidepressant Drugs Major Product Offerings
7.14.4 ROXANE Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.14.5 ROXANE Key News & Latest Developments
7.15 ZYDUS PHARMS
7.15.1 ZYDUS PHARMS Company Summary
7.15.2 ZYDUS PHARMS Business Overview
7.15.3 ZYDUS PHARMS Antidepressant Drugs Major Product Offerings
7.15.4 ZYDUS PHARMS Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.15.5 ZYDUS PHARMS Key News & Latest Developments
7.16 SUN PHARM
7.16.1 SUN PHARM Company Summary
7.16.2 SUN PHARM Business Overview
7.16.3 SUN PHARM Antidepressant Drugs Major Product Offerings
7.16.4 SUN PHARM Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.16.5 SUN PHARM Key News & Latest Developments
7.17 JUBILANT GENERICS
7.17.1 JUBILANT GENERICS Company Summary
7.17.2 JUBILANT GENERICS Business Overview
7.17.3 JUBILANT GENERICS Antidepressant Drugs Major Product Offerings
7.17.4 JUBILANT GENERICS Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.17.5 JUBILANT GENERICS Key News & Latest Developments
7.18 GlaxoSmithKline
7.18.1 GlaxoSmithKline Company Summary
7.18.2 GlaxoSmithKline Business Overview
7.18.3 GlaxoSmithKline Antidepressant Drugs Major Product Offerings
7.18.4 GlaxoSmithKline Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.18.5 GlaxoSmithKline Key News & Latest Developments
7.19 Beijing Wansheng
7.19.1 Beijing Wansheng Company Summary
7.19.2 Beijing Wansheng Business Overview
7.19.3 Beijing Wansheng Antidepressant Drugs Major Product Offerings
7.19.4 Beijing Wansheng Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.19.5 Beijing Wansheng Key News & Latest Developments
7.20 Huahai
7.20.1 Huahai Company Summary
7.20.2 Huahai Business Overview
7.20.3 Huahai Antidepressant Drugs Major Product Offerings
7.20.4 Huahai Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.20.5 Huahai Key News & Latest Developments
7.21 Jianfeng
7.21.1 Jianfeng Company Summary
7.21.2 Jianfeng Business Overview
7.21.3 Jianfeng Antidepressant Drugs Major Product Offerings
7.21.4 Jianfeng Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.21.5 Jianfeng Key News & Latest Developments
7.22 Cadista
7.22.1 Cadista Company Summary
7.22.2 Cadista Business Overview
7.22.3 Cadista Antidepressant Drugs Major Product Offerings
7.22.4 Cadista Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.22.5 Cadista Key News & Latest Developments
7.23 Carbosynth Limited
7.23.1 Carbosynth Limited Company Summary
7.23.2 Carbosynth Limited Business Overview
7.23.3 Carbosynth Limited Antidepressant Drugs Major Product Offerings
7.23.4 Carbosynth Limited Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.23.5 Carbosynth Limited Key News & Latest Developments
7.24 LGM Pharma
7.24.1 LGM Pharma Company Summary
7.24.2 LGM Pharma Business Overview
7.24.3 LGM Pharma Antidepressant Drugs Major Product Offerings
7.24.4 LGM Pharma Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.24.5 LGM Pharma Key News & Latest Developments
7.25 Intellipharmaceutics
7.25.1 Intellipharmaceutics Company Summary
7.25.2 Intellipharmaceutics Business Overview
7.25.3 Intellipharmaceutics Antidepressant Drugs Major Product Offerings
7.25.4 Intellipharmaceutics Antidepressant Drugs Sales and Revenue in Global (2018-2023)
7.25.5 Intellipharmaceutics Key News & Latest Developments
8 Global Antidepressant Drugs Production Capacity, Analysis
8.1 Global Antidepressant Drugs Production Capacity, 2018-2029
8.2 Antidepressant Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Antidepressant Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Antidepressant Drugs Supply Chain Analysis
10.1 Antidepressant Drugs Industry Value Chain
10.2 Antidepressant Drugs Upstream Market
10.3 Antidepressant Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Antidepressant Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
世界の抗うつ薬市場予測2023-2029：SSRI、SNRI、TCA、MAOI、TeCA、NaSSA、RMAO-A阻害剤 |
| 【英語タイトル】Antidepressant Drugs Market, Global Outlook and Forecast 2023-2029 | |
 | ・商品コード：MMG23JU5675 ・発行会社（調査会社）：Market Monitor Global ・発行日：2023年6月 ・ページ数：127 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後2-3営業日） ・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど ・産業分野：医薬品＆医療 |
| Single User（1名様閲覧用） | USD3,250 ⇒換算￥494,000 | 見積依頼/購入/質問フォーム |
| Multi User（20名様閲覧用） | USD4,225 ⇒換算￥642,200 | 見積依頼/購入/質問フォーム |
| Enterprise User（閲覧人数制限なし） | USD4,875 ⇒換算￥741,000 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| 当調査レポートは次の情報を含め、世界の抗うつ薬市場規模と予測を収録しています。・世界の抗うつ薬市場：売上、2018年-2023年、2024年-2029年 ・世界の抗うつ薬市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の抗うつ薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「SSRI」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 抗うつ薬のグローバル主要企業は、Pfizer、 Mylan、 Bayer、 Eli Lilly、 Claire Ellen、 Sanofi S.A、 Meda AB、 Boehringer Ingelheim、 Pierre Fabre、 Cipla、 APOTEX、 PRINSTON INC、 TEVA、 ROXANE、 ZYDUS PHARMS、 SUN PHARM、 JUBILANT GENERICS、 GlaxoSmithKline、 Beijing Wansheng、 Huahai、 Jianfeng、 Cadista、 Carbosynth Limited、 LGM Pharma、 Intellipharmaceuticsなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、抗うつ薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の抗うつ薬市場：タイプ別、2018年-2023年、2024年-2029年 世界の抗うつ薬市場：タイプ別市場シェア、2022年 ・SSRI、SNRI、TCA、MAOI、TeCA、NaSSA、RMAO-A阻害剤 世界の抗うつ薬市場：用途別、2018年-2023年、2024年-2029年 世界の抗うつ薬市場：用途別市場シェア、2022年 ・不安障害、摂食障害、痛み、その他 世界の抗うつ薬市場：地域・国別、2018年-2023年、2024年-2029年 世界の抗うつ薬市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における抗うつ薬のグローバル売上、2018年-2023年 ・主要企業における抗うつ薬のグローバル売上シェア、2022年 ・主要企業における抗うつ薬のグローバル販売量、2018年-2023年 ・主要企業における抗うつ薬のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Pfizer、 Mylan、 Bayer、 Eli Lilly、 Claire Ellen、 Sanofi S.A、 Meda AB、 Boehringer Ingelheim、 Pierre Fabre、 Cipla、 APOTEX、 PRINSTON INC、 TEVA、 ROXANE、 ZYDUS PHARMS、 SUN PHARM、 JUBILANT GENERICS、 GlaxoSmithKline、 Beijing Wansheng、 Huahai、 Jianfeng、 Cadista、 Carbosynth Limited、 LGM Pharma、 Intellipharmaceutics ************************************************************* ・調査・分析レポートの概要 抗うつ薬市場の定義 市場セグメント 世界の抗うつ薬市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の抗うつ薬市場規模 世界の抗うつ薬市場規模：2022年 VS 2029年 世界の抗うつ薬市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの抗うつ薬の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の抗うつ薬製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：SSRI、SNRI、TCA、MAOI、TeCA、NaSSA、RMAO-A阻害剤 抗うつ薬のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：不安障害、摂食障害、痛み、その他 抗うつ薬の用途別グローバル売上・予測 ・地域別市場分析 地域別抗うつ薬市場規模 2022年と2029年 地域別抗うつ薬売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Pfizer、 Mylan、 Bayer、 Eli Lilly、 Claire Ellen、 Sanofi S.A、 Meda AB、 Boehringer Ingelheim、 Pierre Fabre、 Cipla、 APOTEX、 PRINSTON INC、 TEVA、 ROXANE、 ZYDUS PHARMS、 SUN PHARM、 JUBILANT GENERICS、 GlaxoSmithKline、 Beijing Wansheng、 Huahai、 Jianfeng、 Cadista、 Carbosynth Limited、 LGM Pharma、 Intellipharmaceutics ... |
This report aims to provide a comprehensive presentation of the global market for Antidepressant Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antidepressant Drugs. This report contains market size and forecasts of Antidepressant Drugs in global, including the following market information:
Global Antidepressant Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Antidepressant Drugs Market Sales, 2018-2023, 2024-2029, (Units)
Global top five Antidepressant Drugs companies in 2022 (%)
The global Antidepressant Drugs market was valued at US$ 12810 million in 2022 and is projected to reach US$ 13870 million by 2029, at a CAGR of 1.1% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Depression includes a variety of mental health problems characterized by the absence of a positive emotion, low mood, and a range of associated cognitive, physical, emotional, and behavioral symptoms. Antidepressants help maintain balance of various hormones and chemicals in the brain, which helps in the treatment of depression.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Antidepressant Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Antidepressant Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (Units)
Global Antidepressant Drugs Market Segment Percentages, by Type, 2022 (%)
SSRIs
SNRIs
TCAs
MAOIs
TeCAs
NaSSAs
RMAO-A Inhibitors
Global Antidepressant Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (Units)
Global Antidepressant Drugs Market Segment Percentages, by Application, 2022 (%)
Anxiety Disorders
Eating Disorders
Pain
Others
Global Antidepressant Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (Units)
Global Antidepressant Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Antidepressant Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Antidepressant Drugs revenues share in global market, 2022 (%)
Key companies Antidepressant Drugs sales in global market, 2018-2023 (Estimated), (Units)
Key companies Antidepressant Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Mylan
Bayer
Eli Lilly
Claire Ellen
Sanofi S.A
Meda AB
Boehringer Ingelheim
Pierre Fabre
Cipla
APOTEX
PRINSTON INC
TEVA
ROXANE
ZYDUS PHARMS
SUN PHARM
JUBILANT GENERICS
GlaxoSmithKline
Beijing Wansheng
Huahai
Jianfeng
Cadista
Carbosynth Limited
LGM Pharma
Intellipharmaceutics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Antidepressant Drugs, market overview.
Chapter 2: Global Antidepressant Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Antidepressant Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Antidepressant Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Antidepressant Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
❖ レポートの目次 ❖
| ★調査レポート[世界の抗うつ薬市場予測2023-2029：SSRI、SNRI、TCA、MAOI、TeCA、NaSSA、RMAO-A阻害剤] (コード：MMG23JU5675)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の抗うつ薬市場予測2023-2029：SSRI、SNRI、TCA、MAOI、TeCA、NaSSA、RMAO-A阻害剤]についてメールでお問い合わせ |
